Cell dehydration enables massive production of engineered membrane vesicles with therapeutic functions
Quick Facts
- Publication title: Cell dehydration enables massive production of engineered membrane vesicles with therapeutic functions
- Journal: J Extracell Vesicles
- Year: 2024
- DOI: 10.1002/jev2.12483
- PMID/PMCID: 39051765; PMC11270585
Research overview
In this study, we characterize a novel type of EV with promising clinical application potential: dehydration-induced extracellular vesicles (DIMVs). Finally, on animal models, we directly show the biosafety and immunogenicity of DIMV, and investigate its potential application as tumour vaccine or drug carrier in cancer treatment.
Key findings
Extracellular vesicles (EVs) have emerged as promising biomaterials for the treatment of different disease.
However, only handful types of EVs with clinical transformation potential have been reported to date, and their preparation on a large scale under biosafety-controlled conditions is limited.
In this study, we characterize a novel type of EV with promising clinical application potential: dehydration-induced extracellular vesicles (DIMVs).
DIMV is a type of micron-diameter cell vesicle that contains more bioactive molecules, such as proteins and RNA, but not DNA, than previously reported cell vesicles.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Cell dehydration enables massive production of engineered membrane vesicles with therapeutic functions Journal of Extracellular Vesicles. 2024. DOI: 10.1002/jev2.12483. PMID/PMCID: 39051765; PMC11270585.